Linezolid-Resistant Enterococcus faecalis Infection Following Prolonged Low-Dosage Linezolid Treatment for Multidrug-Resistant Tuberculosis

Clin Infect Dis. 2017 Nov 29;65(12):2159-2160. doi: 10.1093/cid/cix729.

Authors

Ilaria Baccani¹, Alberto Antonelli¹, Angelo Galano², Filippo Bartalesi³, Alessandro Bartoloni^{1

3}, Gian Maria Rossolini^{1

2}

Affiliations

¹ Department of Experimental and Clinical Medicine, University of Florence.
² Clinical Microbiology and Virology Unit.
³ Infectious and Tropical Diseases Unit, Florence Careggi University Hospital, Florence, Italy.

PMID: 29020204
DOI: 10.1093/cid/cix729

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibiotics, Antitubercular / adverse effects*
Antibiotics, Antitubercular / therapeutic use
Enterococcus faecalis / drug effects*
Enterococcus faecalis / genetics
Genome, Bacterial
Gram-Positive Bacterial Infections / etiology*
Humans
Linezolid / adverse effects*
Linezolid / therapeutic use
Tuberculosis, Multidrug-Resistant / complications
Tuberculosis, Multidrug-Resistant / drug therapy*
Urinary Tract Infections / drug therapy
Urinary Tract Infections / ethnology*
Urinary Tract Infections / microbiology
Whole Genome Sequencing

Substances

Antibiotics, Antitubercular
Linezolid